MASSBIO PARTNERING WEEK
January 25-29, 2021
Tired of trying to break through the noise during J.P. Morgan Healthcare Conference?
So are we. That’s why MassBio is bringing its first-ever Partnering Week to the Massachusetts startup ecosystem. This week-long event connects major biopharmaceutical organizations with early-stage companies developing breakthrough technologies in complementary focus areas for partnering opportunities. The ultimate goal is to help commercialize innovations so they reach patients in need.
MassBio Partnering Week sponsors are dedicated to researching and developing breakthrough therapies for patients, along with supporting innovation among the startup community in Massachusetts and beyond. Learn more about our sponsors’ key therapeutic areas of interests below and request a one-on-one meeting today. We also encourage life sciences professionals and industry thought leaders to attend each sponsor organization’s plenary session, which you can register for here.
Meet the Sponsors
About: At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain. Partnerships and collaborations are critical to building our neuroscience innovation ecosystem.
Key Therapeutic Areas of Interest: Multiple Sclerosis; Spinal Muscular Atrophy; Alzheimer’s Disease and Dementia; Neuromuscular Disorders; Movement Disorders; Ophthalmology; Immunology; Neurocognitive Disorders; Acute Neurology; and Pain.
Johnson & Johnson Innovation
About: Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists and entrepreneurs with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. We connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients.
Key Therapeutic Areas of Interest: Cardiovascular and Metabolism; Immunology; Infectious Diseases and Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Learn More: jnjinnovation.com
About: EMD Serono aspires to create, improve and prolong life for people living with difficult-to-treat conditions like multiple sclerosis, cancer and infertility. We’re imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. Our company’s global roots take us back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, we have approximately 1,500 employees around the country with commercial, clinical and research operations based in our home state of Massachusetts.
Key Therapeutic Areas of Interest: Oncology; Immuno-oncology; Neurology & Immunology; Fertility; General Medicine; and Endocrinology.
About: BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the U.S., Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the U.S. and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.